Angel is an Associate on the Life Sciences team, and focuses on identifying and creating new ventures.
Angel joined Frazier in 2021 and focuses on identifying and creating new ventures in the life sciences sector.
Prior to joining Frazier, Angel was an Investment Fellow with Vertex Ventures Healthcare. At Vertex, she evaluated early-stage companies pursing transformative biopharmaceutical technologies. Previously, she was the Director of Research and Venture Grants at Emerson Collective, Health. There, she managed a $50 million research fund and designed and implemented operational programs to accelerate oncology preclinical drug development. Prior to Emerson Collective, Angel was the Research Director of the Friedreich Ataxia (FA) Research Alliance, where she managed a $6 million fund and enabled strategic deployment of capital towards emergent therapeutics for FA.
Angel received her Ph.D. in Pharmacology and Cancer Biology from Duke University, where she was a Ruth L. Kirschstein Institutional National Research Service Award Fellow of the National Heart, Lung and Blood Institute. Her dissertation work centered on pharmacologic and genetic modulation of mitochondrial protein deacetylase Sirtuin 3 as a therapy for FA cardiomyopathy.